SCM
NKTR icon

Stevens Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Stevens Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-774
Closed -$251K – 285
2019
Q4 		$251K Buy
+774
New +$224K 0.02% 482
2018
Q4 		– Sell
-4,037
Closed -$3.69M – 837
2018
Q3 		$3.69M Buy
4,037
+2,794
+225% +$2.38M 0.14% 200
2018
Q2 		$910K Sell
1,243
-14
-1% -$16.1K 0.03% 447
2018
Q1 		$2M Buy
+1,257
New +$1.62M 0.08% 288
2017
Q3 		– Sell
-916
Closed -$269K – 1001
2017
Q2 		$269K Buy
+916
New +$265K 0.01% 704
2017
Q1 		– Sell
-1,274
Closed -$234K – 1024
2016
Q4 		$234K Buy
+1,274
New +$259K 0.01% 743
2015
Q3 		– Sell
-2,073
Closed -$389K – 1137
2015
Q2 		$389K Buy
+2,073
New +$357K 0.01% 684
2015
Q1 		– Sell
-1,410
Closed -$328K – 1143
2014
Q4 		$328K Buy
1,410
+444
+46% +$94.9K 0.01% 689
2014
Q3 		$175K Buy
966
+285
+42% +$54.5K 0.01% 881
2014
Q2 		$131K Sell
681
-545
-44% -$96.4K ﹤0.01% 984
2014
Q1 		$223K Sell
1,226
-286
-19% -$56.6K 0.01% 895
2013
Q4 		$257K Buy
+1,512
New +$244K 0.01% 835

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Stevens Capital Management's NKTR Position: Q1 2020 in Review

Stevens Capital Management sold out of Nektar Therapeutics (NKTR) in Q1 2020, closing a stake of 774 shares — an estimated $251K sold.

Stevens Capital Management first reported a position in NKTR in Q4 2013 and held it in 12 quarters. The position peaked at $3.69M in Q3 2018. 244 funds tracked by Wall St. Rank hold NKTR as of Q1 2020.

  • Stevens Capital Management reported no remaining Nektar Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Stevens Capital Management sold 774 Nektar Therapeutics shares in Q1 2020, an estimated $251K.
  • Stevens Capital Management first reported a position in Nektar Therapeutics in Q4 2013 and held it in 12 quarters.
  • Stevens Capital Management's Nektar Therapeutics position peaked at $3.69M in Q3 2018.
  • 244 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2020.

Based on Stevens Capital Management's 13F filing for Q1 2020, filed 21 Apr 2020.